ixoberogene soroparvovec

Ixoberogene soroparvovec (formerly known as ADVM-022) is an investigational gene therapy developed for the treatment of retinal diseases such as neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It utilizes a proprietary adeno-associated virus vector capsid (AAV.7m8) to deliver an optimized aflibercept coding sequence under the control of a strong promoter via a single intravitreal injection. The therapy is designed to provide continuous intraocular production of aflibercept, a VEGF inhibitor, thereby reducing or eliminating the need for frequent anti-VEGF injections and improving long-term vision outcomes. Clinical trials have demonstrated durable expression of aflibercept with significant reduction in treatment burden; however, dose-dependent safety concerns have been observed in DME patients at higher doses[1][3][4][5][6][7][8][9].

Brand names

Ixo-vec

Other names

ADVM-022ADVM022ADVM 022ixo-vecixoberogene soroparvovec